Company Wayland Group Corp. Canadian Securities Exchange
Equities
WAYL
CA9442041062
Pharmaceuticals
Business Summary
Sales per Business
USD in Million | 2016 | Weight | 2017 | Weight | Delta |
---|---|---|---|---|---|
Marijuana Production for Medical Purposes
100.0
%
| 3 | 100.0 % | 2 | 100.0 % | -18.98% |
Sales per region
USD in Million | 2016 | Weight | 2017 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 3 | 100.0 % | 2 | 100.0 % | -18.98% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | - | |
Geoff Kosar
SAM | Sales & Marketing | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 237,260,499 | 237,260,499 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Wayland Group Corp.
845 Harrington Court Unit 3
L7N 3P3, Burlington
+289-288-6274
Sector
1st Jan change | Capi. | |
---|---|---|
+44.36% | 6.29B | |
-13.52% | 4.55B | |
+10.85% | 3.27B | |
-6.52% | 3.23B | |
-0.71% | 2.56B | |
+51.14% | 2B | |
-5.22% | 1.68B | |
+1.29% | 1.64B | |
+57.69% | 1.6B |